Disclosed are compositions and methods useful for oral delivery of targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. The disclosed targeting is useful for oral delivery of therapeutic and detectable agents to diseased tissue in an animal.

Disclosed are compositions and methods useful for oral delivery of targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. The disclosed targeting is useful for oral delivery of therapeutic and detectable agents to diseased tissue in an animal.

The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.

The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.

This disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof: in which m, p, A, Ar.sup.1, Ar.sup.2, Ar.sup.3, R.sup.1, R.sup.2, and R.sup.3 are defined in the specification. The compounds of formula (I) can be used as CGRP antagonists and can be used to treat

##STR00001##

This disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof: in which m, p, A, Ar.sup.1, Ar.sup.2, Ar.sup.3, R.sup.1, R.sup.2, and R.sup.3 are defined in the specification. The compounds of formula (I) can be used as CGRP antagonists and can be used to treat

##STR00001##

The invention provides a method of treating pathogenic bacterial infection (e.g., tuberculosis infection) in an animal comprising administering a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal. The invention also provides methods of treating chronic granulomatous disease and Wegener's granulomatosis in an animal comprising administering a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal.

[Problem to be Solved]

To provide a compound for removing pluripotent cells from a cell population potentially containing the pluripotent cells.

[Solution]

A polyphenylalanine derivative is contacted with a cell population of interest.

Disclosed herein are methods and compositions for identification of specific DNA binding domains for constructing highly specific nucleases, which allows for pristine genome editing.

Disclosed herein are methods and compositions for identification of specific DNA binding domains for constructing highly specific nucleases, which allows for pristine genome editing.